S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:VIR

Vir Biotechnology (VIR) Stock Price, News & Analysis

$10.10
+0.13 (+1.30%)
(As of 03/27/2024 ET)
Today's Range
$9.78
$10.24
50-Day Range
$8.60
$11.90
52-Week Range
$7.72
$27.48
Volume
995,068 shs
Average Volume
971,068 shs
Market Capitalization
$1.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.38

Vir Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
240.3% Upside
$34.38 Price Target
Short Interest
Bearish
6.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Vir Biotechnology in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$748,647 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.04) to ($3.87) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.96 out of 5 stars

Medical Sector

615th out of 939 stocks

Biological Products, Except Diagnostic Industry

103rd out of 156 stocks

VIR stock logo

About Vir Biotechnology Stock (NASDAQ:VIR)

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

VIR Stock Price History

VIR Stock News Headlines

Buy Friday, Sell Monday, No Exceptions
Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.
VIR Jul 2024 17.500 call
Vir Biotechnology, Inc. (VIR)
CBOE shift unlocks new weekend income strategy
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend.
VIR Oct 2024 20.000 call
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Q4 2023 Vir Biotechnology Inc Earnings Call
See More Headlines
Receive VIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/27/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VIR
Fax
N/A
Employees
587
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.38
High Stock Price Target
$110.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+240.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-615,060,000.00
Net Margins
-713.69%
Pretax Margin
-728.93%

Debt

Sales & Book Value

Annual Sales
$86.18 million
Book Value
$11.82 per share

Miscellaneous

Free Float
110,591,000
Market Cap
$1.36 billion
Optionable
Optionable
Beta
0.42
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Ann M. Hanly Ph.D. (Age 53)
    Executive VP & Chief Technology Officer
    Comp: $842.23k
  • Dr. Phillip Pang M.D. (Age 48)
    Ph.D., Executive VP & Chief Medical Officer
    Comp: $837.38k
  • Dr. Marianne De Backer M.B.A. (Age 54)
    M.Sc., Ph.D., CEO & Director
  • Dr. Klaus Frueh Ph.D. (Age 64)
    Co-Founder & Scientific Advisor
    Comp: $177.66k
  • Dr. Lawrence Corey M.D. (Age 76)
    Co-Founder & Scientific Advisor
  • Dr. Louis J. Picker M.D.
    Co-Founder & Scientific Advisor
  • Mr. Sung H. Lee (Age 54)
    Executive VP & CFO
  • Dr. Jennifer Eileen Towne Ph.D.
    Executive VP & Chief Scientific Officer
  • Ms. Heather Rowe Armstrong
    Vice President of Investor Relations
  • Ms. Vanina De Verneuil J.D.
    Executive VP, General Counsel & Corporate Secretary

VIR Stock Analysis - Frequently Asked Questions

Should I buy or sell Vir Biotechnology stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VIR shares.
View VIR analyst ratings
or view top-rated stocks.

What is Vir Biotechnology's stock price target for 2024?

7 brokers have issued 1-year target prices for Vir Biotechnology's stock. Their VIR share price targets range from $10.00 to $110.00. On average, they expect the company's share price to reach $34.38 in the next twelve months. This suggests a possible upside of 240.3% from the stock's current price.
View analysts price targets for VIR
or view top-rated stocks among Wall Street analysts.

How have VIR shares performed in 2024?

Vir Biotechnology's stock was trading at $10.06 on January 1st, 2024. Since then, VIR stock has increased by 0.4% and is now trading at $10.10.
View the best growth stocks for 2024 here
.

When is Vir Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our VIR earnings forecast
.

How were Vir Biotechnology's earnings last quarter?

Vir Biotechnology, Inc. (NASDAQ:VIR) announced its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.14) by $0.28. The business earned $16.80 million during the quarter, compared to the consensus estimate of $11.18 million. Vir Biotechnology had a negative net margin of 713.69% and a negative trailing twelve-month return on equity of 34.92%. The business's revenue was down 66.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.76) EPS.

What is George Scangos' approval rating as Vir Biotechnology's CEO?

7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees.

When did Vir Biotechnology IPO?

Vir Biotechnology (VIR) raised $149 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO.

Who are Vir Biotechnology's major shareholders?

Vir Biotechnology's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.14%), Vanguard Group Inc. (9.11%), Baillie Gifford & Co. (2.95%), Bridgeway Capital Management LLC (1.00%), Northern Trust Corp (0.70%) and Charles Schwab Investment Management Inc. (0.56%). Insiders that own company stock include Ann M Hanly, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Vicki L Sato and Vicki L Sato.
View institutional ownership trends
.

How do I buy shares of Vir Biotechnology?

Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VIR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners